Barusiban

Barusiban (INN) (code name FE-200440) is a non-peptide drug which is among the most potent and selective oxytocin receptor antagonists known.[1][2] It was trialed by Ferring Pharmaceuticals as a treatment of preterm labor but failed to demonstrate effectiveness and was not pursued any further.[1][3]

Barusiban
Clinical data
ATC code
  • None
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC40H63N9O8S
Molar mass830.06 g·mol−1
3D model (JSmol)

See also

References

  1. Rainer Landgraf; Inga D. Neumann (10 September 2008). Advances in Vasopressin and Oxytocin - From Genes to Behaviour to Disease. Elsevier. pp. 194, 489. ISBN 978-0-08-093247-7.
  2. Stefan Offermanns; Walter Rosenthal (14 August 2008). Encyclopedia of Molecular Pharmacology. Springer Science & Business Media. pp. 1278–. ISBN 978-3-540-38916-3.
  3. Richard Ouellette; Joseph Joyce (25 October 2010). Pharmacology for Nurse Anesthesiology. Jones & Bartlett Publishers. pp. 450–. ISBN 978-0-7637-8607-6.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.